

Frances R Balkwill

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5070949/frances-r-balkwill-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

17,055
citations

35
h-index

58
g-index

58
ext. papers

19,613
ext. citations

14
avg, IF

6.9
L-index

#	Paper	IF	Citations
53	Harnessing cytokines and chemokines for cancer therapy.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	15
52	Cells are Us - combining research and public engagement. <i>Nature Reviews Cancer</i> , 2021 , 21, 277-278	31.3	1
51	Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2021 , 9, 665-681	12.5	4
50	A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion. <i>IScience</i> , 2021 , 24, 102676	6.1	10
49	Modelling TGFB and Hh pathway regulation of prognostic matrix molecules in ovarian cancer. <i>IScience</i> , 2021 , 24, 102674	6.1	5
48	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021 , 81, 5706-5719	10.1	9
47	Airway dendritic cell maturation in children exposed to air pollution. <i>PLoS ONE</i> , 2020 , 15, e0232040	3.7	1
46	Cancer associated fibroblast FAK regulates malignant cell metabolism. <i>Nature Communications</i> , 2020 , 11, 1290	17.4	53
45	Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. <i>Cell Reports</i> , 2020 , 30, 525-540.e7	10.6	34
44	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 1803-1810	8.7	11
43	Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2020 , 80, 4946-4959	10.1	14
42	Interest and learning in informal science learning sites: Differences in experiences with different types of educators. <i>PLoS ONE</i> , 2020 , 15, e0236279	3.7	4
41	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019 , 125, 1963-1972	6.4	22
40	Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 172	7.3	35
39	Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. <i>Endocrine-Related Cancer</i> , 2019 , 26, 853-865	5.7	22
38	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018 , 8, 304-319	24.4	157
37	Mets and NETs: The Awakening Force. <i>Immunity</i> , 2018 , 49, 798-800	32.3	3

36	A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. <i>Clinical Cancer Research</i> , 2017 , 23, 250-262	12.9	88
35	Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. <i>Journal of Proteome Research</i> , 2017 , 16, 3083-3091	5.6	106
34	A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. <i>Journal of Clinical Investigation</i> , 2017 , 127, 801-813	15.9	49
33	CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016 , 76, 6118-6129	10.1	83
32	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3025-36	12.9	80
31	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , 2016 , 7, 15648-61	3.3	11
30	Interleukin-6 Stimulates Defective Angiogenesis. <i>Cancer Research</i> , 2015 , 75, 3098-107	10.1	132
29	Inflammation and cancer: advances and new agents. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 584-96	19.4	601
28	Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. <i>Cancer Research</i> , 2015 , 75, 1255-64	10.1	35
27	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
26	Centre of the Cell: Science Comes to Life. <i>PLoS Biology</i> , 2015 , 13, e1002240	9.7	4
25	Murine CD27(-) Vβ(+) T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3562-70	11.5	129
24	Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. <i>Journal of Pathology</i> , 2014 , 232, 43-56	9.4	46
23	Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. <i>FASEB Journal</i> , 2013 , 27, 4244-53	0.9	16
22	B regulatory cells in cancer. <i>Trends in Immunology</i> , 2013 , 34, 169-73	14.4	88
21	Cancer-related inflammation: common themes and therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2012 , 22, 33-40	12.7	471
20	The chemokine system and cancer. <i>Journal of Pathology</i> , 2012 , 226, 148-57	9.4	301
19	The peritoneal tumour microenvironment of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012 , 227, 136-45	9.4	41

18	Paraneoplastic thrombocytosis in ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 610-8	59.2	505
17	A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. <i>Cancer Research</i> , 2012 , 72, 66-75	10.1	158
16	B regulatory cells and the tumor-promoting actions of TNF- α during squamous carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 10662-7	11.5	243
15	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
14	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2538-48	12.9	182
13	Interleukin-6 as a therapeutic target in human ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 6083-96	12.9	291
12	Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. <i>Journal of Immunology</i> , 2010 , 185, 183-9	5.3	48
11	Tumour necrosis factor and cancer. <i>Nature Reviews Cancer</i> , 2009 , 9, 361-71	31.3	1175
10	The tumor-promoting actions of TNF- α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3011-23	15.9	236
9	Cancer-related inflammation. <i>Nature</i> , 2008 , 454, 436-44	50.4	7367
8	"Re-educating" tumor-associated macrophages by targeting NF-kappaB. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1261-8	16.6	630
7	Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4542-9	2.2	187
6	The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. <i>Cancer Research</i> , 2007 , 67, 585-92	10.1	304
5	Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. <i>Journal of Immunology</i> , 2005 , 175, 1197-205	5.3	357
4	The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. <i>Cancer Research</i> , 2005 , 65, 10355-62	10.1	130
3	Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. <i>Clinical Cancer Research</i> , 2003 , 9, 84-92	12.9	58
2	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. <i>Cancer Research</i> , 2002 , 62, 5930-8	10.1	320
1	Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. <i>Nature Medicine</i> , 1999 , 5, 828-31	50.5	706

